ReviewPharmaceuticals (Basel, Switzerland)2021
RNA Phage VLP-Based Vaccine Platforms.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Armored RNA technology as a clinical diagnostics tool for future pandemic preparedness.Journal of microbiology (Seoul, Korea) · 2026Review
- Immunization with VLP-based vaccines induces high IgG antibody titers in dermal interstitial fluid.NPJ vaccines · 2025Article
- Role of the Virome in Vaccine-Induced Immunization.Vaccines · 2025Review
- Two doses of Qβ virus like particle vaccines elicit protective antibodies against heroin and fentanyl.NPJ vaccines · 2025Article
- MS2 virus-like particles as a versatile platform for multi-disease vaccines: a review.Frontiers in immunology · 2025Review
- Article
- Effect of coat-protein concentration on the self-assembly of bacteriophage MS2 capsids around RNA.Nanoscale · 2024Article
- Article
- Antigen self-anchoring onto bacteriophage T5 capsid-like particles for vaccine design.NPJ vaccines · 2024Article
- Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response.Frontiers in immunology · 2024Review
- MS2 Virus-like Particles as a Versatile Peptide Presentation Platform: Insights into the Deterministic Abilities for Accommodating Heterologous Peptide Lengths.ACS synthetic biology · 2023Article
- RNA and Single-Stranded DNA Phages: Unveiling the Promise from the Underexplored World of Viruses.International journal of molecular sciences · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Virus-like particles from a variety of RNA bacteriophages have turned out to be useful platforms for delivery of vaccine antigens in a highly immunogenic format. Here we update the current state of development of RNA phage VLPs as platforms for presentation of diverse antigens by genetic, enzymatic, and chemical display methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.